ClinicalTrials.gg
RecruitingNCT07323914CALM-DUpdated Jan 7, 2026

Clinical Analgesic Management in Dementia

A Phase 3 interventional study of Tylex in Alzheimer Disease, sponsored by Xuanwu Hospital, Beijing. Recruiting at 1 site in China. Open to participants aged 50 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-01-07.

Sponsored by Xuanwu Hospital, Beijing · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Mar 2025, registered Dec 2025).
  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
50 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 26 studies in Alzheimer Disease by Xuanwu Hospital, Beijing — 19 open to participants now, 20 under way, 1 of them phase 3. Alzheimer Disease · Xuanwu Hospital, Beijing.

Planned enrollment
16th of 19
10 · median 40
Started
2025
with 7 others
Phase 3
Only one
of the 26
Primary completion
2027-01
later than 7 of 19 live
Registered
21st of 26
by date

Among the 26 studies in Alzheimer Disease by Xuanwu Hospital, Beijing, this one is the 16th largest by planned enrollment of the 19 interventional ones that give a count, is one of 8 that started in 2025, is the only one in phase 3, reaches primary completion later than 7 of the 19 other live ones, and was the 21st registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

19 of the 26 studies in Alzheimer Disease by Xuanwu Hospital, Beijing are open now, in 1 country. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 19 open studies →

Where they have run

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 50 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Alzheimer Disease by Xuanwu Hospital, Beijing, or all of them as a file.
02

Study summary

This study is designed to assess the efficacy and safety of oxycodone in managing moderate to severe pain in patients with Alzheimer's disease. The trial will be conducted at Xuanwu Hospital, Capital Medical University, and will enroll 10 eligible participants. Participants will receive oxycodone/acetaminophen (5 mg/325 mg) once daily for 12 weeks. The treatment will follow international guidelines, with dosages adjusted based on the patient's baseline pain levels and individual needs. Dosages will be adjusted based on baseline pain levels and patient needs, following international guidelines. Efficacy and adverse events will be assessed at baseline, week 6, week 12, and at a 12-week post-treatment follow-up. The primary outcome is change in VAS pain scores; secondary outcomes include PAINAD, SF-36, functional ability, and safety profiles.

03

Conditions studied

  • Alzheimer Disease

Keywords

  • Alzheimer disease
  • chronic pain
  • opioid drugs
04

Who can participate

Ages eligible
50 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, aged 50 to 90 years at the time of enrollment.
  • Meets the NIA-AA core clinical diagnostic criteria for probable Alzheimer's disease.
  • Clinical Dementia Rating - Global Score (CDR-GS) between 0.5 and 2.0, inclusive, and Clinical Dementia Rating - Memory Box (CDR-MB) score ≥ 0.5.
  • Diagnosed with chronic pain within 6 months prior to enrollment and considered appropriate for opioid therapy.
  • Presence and severity of pain confirmed using PAINAD, MOBID-2, or comparable scales.
  • Educational attainment: at least 4-6 years of formal education, or not illiterate.
  • If currently receiving psychotropic or cognitive-enhancing medications, the dosage must have been stable for at least 3 months prior to study entry and remain unchanged during the study. Unless otherwise specified, all other permitted concomitant medications (non-AD related) must be stably administered for at least 4 weeks prior to baseline.
  • Has a reliable caregiver/companion who can assist with study participation, defined as a person who can support the participant throughout the study and spend at least 8 hours per week with the participant.
  • Willing and able to participate in this clinical trial, to maintain the assigned intervention during the study period, and has signed the form.

Exclusion criteria

Exclusion Criteria:

  • History of (TIA), stroke, or seizure within the past 12 months.
  • Presence of any psychiatric diagnosis or symptoms that may interfere with study participation (e.g., hallucinations, major depression, or delusions).
  • Known allergy to opioid analgesics.
  • Severe visual or hearing impairment.
  • Alcohol dependence, substance abuse, or other drug addiction or addictive tendency.
  • Current participation in another study related to the treatment of Alzheimer's disease.
  • Any other uncontrolled or inadequately treated medical condition (e.g., cardiac, respiratory, gastrointestinal, hepatic, or renal disease), or any condition judged by the investigator to compromise participant safety or interfere with study assessments.
  • Any other reason deemed by the investigator to preclude participation in the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Tylex group

    Drug: Tylex

Interventions

  • DrugTylex

    Tylenol (compound oxycodone/acetaminophen) is a non-narcotic analgesic that combines a lower dose of oxycodone (5 mg) with acetaminophen (325 mg). Compared to OxyContin, it provides milder opioid potency and utilizes a synergistic mechanism to achieve pain control with reduced risk of opioid-related side effects.

06

What researchers measure

Primary outcomes

  1. Pain Assessment in Advanced Dementia Scale (PAINAD)

    Time frame: baseline, 6 weeks, 12 weeks, 24 weeks.

Secondary outcomes

  1. Changes from baseline of exploratory blood biomarkers

    Description: Exploratory blood biomarkers related to astrocyte-neuron interactions will be assessed using the SomaScan 11k platform. These include glial fibrillary acidic protein (GFAP), S100B, YKL-40, β-synuclein, neuregulin 1, GluN2A, and neurogranin.

    Time frame: baseline; 12 weeks.

  2. Mobilization-Observation-Behavior-Intensity-Dementia Pain Scale, version 2 (MOBID-2)

    Time frame: baseline, 6 weeks, 12 weeks, 24 weeks.

  3. Change from Baseline in Brain Amyloid Plaque Deposition as measured by PET Scan

    Time frame: baseline; 12 weeks.

  4. Change from baseline on the Neuropaychiatic Inventory (NPI)

    Time frame: baseline; 6 weeks; 12 weeks; 24 weeks.

  5. Change from baseline on the Alzheimer's Disease Cooperative study-Activities of Daily Living Scale(ADCS-ADL)

    Time frame: baseline; 6 weeks; 12 weeks; 24 weeks.

  6. Change from baseline on the Alzheimer's Disease Cooperative study-clinical global impression of change scale(ADCS-CGIC)

    Time frame: baseline; 6 weeks; 12 weeks; 24 weeks.

  7. Change from baseline on the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB)

    Time frame: baseline; 6 weeks; 12 weeks; 24 weeks.

  8. Change from baseline on the Mini Mental state Examination (MMSE) score

    Time frame: baseline; 6 weeks; 12 weeks; 24 weeks.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Jan 2027, 22 months after the start.

Of 101 phase 3 interventional studies under Alzheimer Disease, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 73. This study's planned 22 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2025
First posted
Jan 7, 2026
StartActual
Mar 1, 2025
Primary completionEst.
Jan 1, 2027
CompletionEst.
Mar 31, 2027
Last update
Jan 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07323914
Responsible party
Sponsor
First posted
Jan 7, 2026
Start date
Mar 1, 2025
Primary completion
Jan 1, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Jan 7, 2026

Study contacts

Yi Tang, M.D., Ph.D.
Contact
tangyi@xwhosp.org
00861083199456
Ouyang Chen, Ph.D.
Contact
chenouyang@xwhosp.org
15652888562
Yi Tang
study chair · M.D., Ph.D.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion